The positive start to 2025 continued in the second quarter, with stable organic growth in order intake and sales, and our margins strengthened despite strong headwinds from tariffs and negative currency effects,” says Mattias Perjos, President & CEO at Getinge. The medtech company’s net sales increased organically by 4.1% while order intake rose by 4.4% organically.
Business area Acute Care Therapies continues to be successful in handling the increased demand for ventilators, and the order intake in ECLS consumables remains high. The positive trend for Sterile Transfer in Life Science strengthened during the quarter, while the rationalizations in Getinge’s Bio-Processing business are fully underway.
“This means that we will be well positioned for profitable growth in Bio-Processing when demand returns. In Surgical Workflows, Infection Control and Digital Health Solutions delivered significant growth,” says Mattias Perjos, President & CEO.
Paragonix, acquired in the autumn of 2024, continues to impress, with another sales record in the quarter. The operations also made a positive contribution to Getinge’s EBITA margin, slightly earlier than expected.
Another important milestone for Getinge was the first use of the next generation of endoscopic vessel harvesting (EVH) product, Vasoview Hemopro 3, in clinical procedures in the US.
“The results were positive, and we expect to start deliveries on a larger scale during the third quarter,” Perjos tells. “In Life Science, we launched a new washer and in Surgical Workflows we continue to strengthen our offering in consumables, where we have achieved high growth. Surgical Workflows also entered an exciting partnership with Zimmer Biomet that enhances our presence in the rapidly growing ASC segment in the US market.”
Adjusted EBITA increased in the quarter, despite close to -270 MSEK in tariffs and negative currency effects compared with last year.
“We were once again successful in adjusting prices, but short term we have been forced to absorb most of the tariff costs. Accordingly, we are also analyzing opportunities to adapt the company’s costs and supply chain over time to these new rules of the game. We are well positioned to manage these challenges by leveraging our leading position in key niches that meet long-term increasing healthcare needs,” explains Perjos.
In light of the tariff levels noted in the second quarter, Getinge sees no need to change its long-term financial target.
Given our performance and dialogue with customers, my outlook for the remainder of 2025 is positive, even though geopolitical risk is elevated. I would like to thank all of our customers and employees for their important efforts in creating value for clinical staff and patients,” says Perjos.
Read Also: EQT to acquire Adalvo, a leading B2B dossier developer
